


TULSA-PRO Ablation Clinical Trial (TACT)

Interim 5-year follow-up


BACKGROUND

115
Male
Participants



Age Range **45 - 80**

Prostate
Volume up to
125cc



13 Clinical Sites
Across US, Canada & Europe

Prostate Cancer Risk

33% Low Risk | **67%** Intermediate Risk

ISUP Grade Group 1-2


RESULTS

Erectile Function	Urinary Continence	No Urethral Stricture	No Rectal Injury
87% of men	97% of men	97% of men	100% of men
Reported erection firmness sufficient for penetration by 5 years. (Patients were previously potent).	Remained continent at 5 years.	Reported no urethral stricture.	Reported no rectal injury, grade 4 event or fistula.

Effective prostate ablation

At 1 year, the median perfused prostate volume significantly reduced by:

92%



PSA primary efficacy endpoint resolutely met:

96% (91 - 98)	Median (IQR) PSA reduction	0.26 ^{ng} / _{ml} (0.10 - 0.53)	Median (IQR) PSA nadir	By 5 years 21% of men	underwent additional intervention for their prostate cancer (first treatment performed by first-time users considering original patient exclusion criteria)
-------------------------	----------------------------	--	------------------------	------------------------------	---

Overall histological benefit

Overall histological improvement (eradication of GG2, downgrading from high to low-volume GG1, or eradication of GG1 disease) occurred in:


75 - 80%
of men across all risk subgroups




Scan to learn more!

What is TULSA-PRO?

- ✔ Transurethral
- ✔ MRI-Guided
- ✔ Autonomous-Robotics
- ✔ Radiation-Free
- ✔ Incision-Free



The TULSA-PRO Advantage

Profound Medical develops and distributes customizable, incision-free ablative therapies, while offering **Genius Services** to provide partners with support and resources at every stage of adoption.

The TULSA-PRO Advantage				
Reimbursement Team	Service Team	Marketing Team	Clinical Team	PRO-Talk Academy